Napabucasin (BBI608), an orally administered STAT3 inhibitor, has undergone clinical evaluation for treating various cancers (Hubbard and Grothey, 2017; Froeling et al., 2019; Bitsch et al., 2022; Bekaii-Saab et al., 2023; Jing et al., 2023). Here, STAT3 is linked to cancer.